Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Levonorgestrel (Kyleena®) is recommended as an option for use within NHS Wales for contraception for up to five years. |
|||
|
|||
Medicine details |
|||
| Medicine name | levonorgestrel (Kyleena®) | ||
| Formulation | 19.5 mg intrauterine delivery system | ||
| Reference number | 3582 | ||
| Indication | Contraception for up to five years |
||
| Company | Bayer plc | ||
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1318 | ||
| NMG meeting date | 11/07/2018 | ||
| AWMSG meeting date | 12/09/2018 | ||
| Date of issue | 20/09/2018 | ||
| Date of last review | April 2022 | ||
| Further information This appraisal recommendation was reviewed in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations. |
|||